FDA approves clinical trials for medical cannabis to treat PTSD in military veterans
Green Market Report
Wed, Nov 20
Key Points
- The FDA has approved a clinical trial to study the use of medical marijuana for military veterans with post-traumatic stress disorder who are currently smoking or vaping cannabis.
- The study, referred to as MJP2, faced a three-year battle before receiving approval from the FDA.
- The trial aims to investigate the effectiveness of medical marijuana in treating PTSD among veterans.
- Accessing the full article requires logging in to read all 447 words.
Following a three-year-long fight, the U.S. Food and Drug Administration has finally given its blessing to a proposed clinical trial to study the efficacy of medical marijuana for military veterans who are smoking or vaping cannabis to treat post-traumatic stress disorder.
The study, formally called MJP2, was only greenlit by the...
Please login to read all 447 words.
Discover